Travere Therapeutics Inc. (TVTX)
NASDAQ: TVTX
· Real-Time Price · USD
24.64
0.42 (1.73%)
At close: Oct 03, 2025, 3:59 PM
24.00
-2.60%
After-hours: Oct 03, 2025, 06:30 PM EDT
1.73% (1D)
| Bid | 23.48 |
| Market Cap | 2.2B |
| Revenue (ttm) | 333.87M |
| Net Income (ttm) | -169.06M |
| EPS (ttm) | -2.02 |
| PE Ratio (ttm) | -12.2 |
| Forward PE | 60.55 |
| Analyst | Buy |
| Dividends | n/a |
| Ask | 25.5 |
| Volume | 1,154,897 |
| Avg. Volume (20D) | 2,070,650.4 |
| Open | 24.51 |
| Previous Close | 24.22 |
| Day's Range | 24.32 - 25.43 |
| 52-Week Range | 12.91 - 28.69 |
| Beta | 0.84 |
| Ex-Dividend Date | n/a |
About TVTX
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol TVTX
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for TVTX stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsTravere Therapeutics Inc. is scheduled to release its earnings on
Oct 30, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
3 weeks ago
+26.2%
Travere Therapeutics shares are trading higher aft...
Unlock content with
Pro Subscription
1 month ago
+1.49%
Travere Therapeutics shares are trading higher after HC Wainwright & Co. raised its price target on the stock from $30 to $47.
3 weeks ago · seekingalpha.com
Travere Therapeutics: Buy Rating On Back Of Filspari Expansion Towards FSGSInitiating coverage on Travere Therapeutics with a "Buy: rating, citing strong growth potential for its kidney drug Filspari (sparsentan). Company's Filspari is FDA-approved for IgAN, with Q2 2025 U.S...
3 weeks ago · seekingalpha.com
Travere: No AdCom, No Problem - Targeting Big Revenues With FSGS ApprovalI am upgrading Travere Therapeutics, Inc. to a Buy, as the FDA's decision not to hold an AdCom suggests a favorable path for Filspari in FSGS. Filspari's strong sales growth, improved financials, and ...
